biotechnology Archives | Research & Innovation

Dean Janusz Kozinkski on the Faculty of Science & Engineering's India mission objectives

fmaquito — Wed, 02 Mar 2011 10:00:00 +0000

Researchers from the at Toronto's 91��ɫ are currently on a mission to establish key partnerships and collaborations with Indian research organizations and educational institutions, wrote Mumbai's The Hindu Business Line Feb. 27. The delegation of 12 researchers is visiting several top-tier universities and institutes across the country such as the IITs at Chennai and Mumbai, the Indian Space Research Organisation, the Tata Institute of Fundamental Research and the University of Kolkata, to name a few.

The key mandate for these meetings is to enable researchers from 91��ɫ and from across India to establish joint bilateral research and developmental projects. 91��ɫ, the third largest university in Canada, is the country's leading interdisciplinary research and teaching institution with an academic community of 50,000 students and 7,000 faculty and staff, as well as 200,000 alumni worldwide.

Leader of the delegation is , dean of the Faculty of Science & Engineering, and professor in 91��ɫ’s Department of Earth & Space Sciences & Engineering. Among others, Kozinski's brainchild is an anti-terrorism project evocatively called eWAR (Early Warning & Advance Response) system that seeks to detect, quantify and initiate an effective response to chemical and biological agents released in public buildings.

In a special interview to Business Line during his visit to this newspaper office in Mumbai despite a hectic schedule, Kozinski shared for the benefit of readers the mission's objectives, research priorities, funding and related matters:

Kozinski: India is one of our three focal points. We want to engage in projects with practical social applications. Specifically, we are looking at, among other areas, space science which would cover micro and nano satellites to carry communications tools. Our focus would also be atmospheric monitoring to study global warming and climate change.

Also, we are keen to develop partnerships in the field of biotechnology for healthcare; analyse propagation of infectious diseases – their origin, spread, control and eradication through bio-sensors.

We firmly believe in creating value and sharing it with the society. Where societal benefits are involved, I am somewhat wary of creating barriers like intellectual property rights and so on. We want the society at large to benefit from our research.

Republished courtesy of YFile – 91��ɫ’s daily e-bulletin.

The post Dean Janusz Kozinkski on the Faculty of Science & Engineering's India mission objectives appeared first on Research & Innovation.

NSERC awards over $1 million to 91��ɫ-led research partnerships

fmaquito — Fri, 21 Jan 2011 10:00:00 +0000

Funding supports projects in 3D film and personalized cancer diagnosis over three years

Two 91��ɫ-led industry-academic partnerships have received a total of $1,237,136 through the 's (NSERC) Strategic Projects Grants program.

Sergey Krylov, professor in the Faculty of Science & Engineering and Canada Research Chair in Bioanalytical Chemistry, has received $773,200 over three years to explore new therapies to treat metastatic cancers – secondary tumors that originate from a malignant primary tumor and subsequently invade different organs.

Right: Sergey Krylov

Laurie Wilcox, associate professor in the Faculty of Health’s Department of Psychology, is co-principal investigator on Depth in Motion with Ali Kazimi, associate professor in the Faculty of Fine Arts’ Department of Film. Theirs will be the first research project to rigorously assess human responses to moving content in stereoscopic 3D film (S3D), while challenging current practices and intuitions filmmakers have garnered through 2D and static 3D experience. The grant is provided through a collaborative initiative between NSERC and the ; NSERC has provided $286,836 while the Canada Council has provided $177,100 for a cumulative three-year total of $463,936.

Left: Laurie Wilcox

Krylov has partnered with , whose Canadian offices are based in Concord, Ontario, to create personalized diagnoses and therapy monitoring for metastatic cancers. Current difficulties in detecting and eradicating these tumors significantly contribute to cancer mortality rates; therapies that are efficient for one patient often do not work for others. Their research uses "aptamers" – short DNA strands capable of selectively binding molecules on cell surfaces to serve as tracers for metastatic cancer tumors and, potentially, as vehicles to deliver drugs to metastatic cells.

Wilcox and Kazimi will collaborate with , associate professor in the Faculty of Science & Engineering’s Department of Computer Science & Engineering and member of the , to create an independent S3D film installation based on a piece of dance choreography and presented in both a large-scale S3D projection format and on multiple S3D displays. Audience members will move through a gallery space and choose to view the large-scale screen or one of the alternative displays containing different motion in depth sequences. The project will evaluate movement’s effect through depth on observer preferences, determine if these preferences are contingent on the nature of the movement, and determine if pacing differences exist between 2D and S3D film content.

Right: Ali Kazemi

Jim Mirkopolos, vice-president of operations for Toronto-based , is the project’s industry collaborator; Cinespace's Kleinburg studios are providing space to set up and test the installation later in the project.

“These projects build on 91��ɫ’s expanding expertise in digital media and life science research, and our value-added industry-academic partnerships,” said Stan Shapson, vice-president Research & Innovation. “Depth in Motion is a natural next step in the 3D film research 91��ɫ began through the in partnership with Toronto-based industry leaders, and demonstrates the innovation unleashed when the creative arts and science converge. Professor Krylov’s work with in 91��ɫ Region has a six-year history that involves two past successful collaborations and will further contribute 91��ɫ’s scientific expertise to the region’s growing and vibrant biotech sector.”

91��ɫ’s projects were among 120 chosen to receive a total of $55 million in funding under NSERC’s Strategic Project Grants program, which aims to turn the results of academic research into real benefits for Canadians.

The announcement was made by Gary Goodyear, minister of state (Science & Technology) in Waterloo, Ontario. “Supporting science and research is critical to Canada’s future economic growth,” said Goodyear. “This investment will bring together 100 teams of some of the world’s top researchers to work with industry on promising new projects that will help strengthen our economy, create jobs and bring other benefits to communities.”

“These Strategic Project Grants show that the NSERC community has risen to the challenge and is putting the federal S&T strategy to work,” said NSERC President Suzanne Fortier. “We received a high number of quality submissions, and the peer review committees were impressed with the research teams’ excellence, their proposals’ importance and potential impact, and the strong support from partners.”

For a complete list of NSERC recipients, visit the website.

By Elizabeth Monier-Williams, research communications officer.

The post NSERC awards over $1 million to 91��ɫ-led research partnerships appeared first on Research & Innovation.

YORKbiotech announces winners of Sanofi pasteur Healthcare and Biotechnology Venture Challenge

fmaquito — Fri, 05 Mar 2010 10:00:00 +0000

What do you get when you match an inventor with a business student? Among many things, you get a commercialization plan for a new product or discovery that could potentially transform health care.

That was the case in YORKbiotech's sanofi pasteur Healthcare and Biotechnology Venture Challenge 2009 competition, which matched students enrolled in the MBA Program in 91��ɫ's Schulich School of Business with inventors of viable health-care inventions to devise market strategies and goals to commercialize new products. Industry mentors were on hand to offer teams advice and guidance. Each team consisted of two students working with product inventors and a mentor for a chance to win more than $17,000 in prizes.

Above: From left, Gavin Zealey (contest judge), scientist Arjen Bogaards and MBA students Dilip Chary and Saif Mohamed

The project, which started last fall, saw teams work with the inventors to learn about the product and then create a commercialization plan before Nov. 29, 2009.

In the final stage of the competition, three shortlisted teams pitched their invention commercialization plans to a panel of judges in a session that resembled an episode from “Dragons' Den”, the popular CBC Television venture-capitalist show. Industry experts Gavin Zealey, executive director of corporate development for sanofi pasteur Ltd.; Borys Chabursky, founder and president of SHI Consulting Inc.; and Janet Lambert, president & CEO with Lambert BioConsulting, served as the competition's judges.

The winners of the 2009 sanofi pasteur Healthcare & Biotechnology Venture Challenge are:

Sono Pharmaceuticals Inc., which placed first for its venture involving photodynamic therapy and sonodynamic therapy to produce an immune-therapeutic response to treat certain cancers. The team includes scientific entrepreneur Arjen Bogaards and MBA students Dr. Dilip Chary (who is also a family practitioner) and Saifuddin Tajuddin Mohamed. The team was awarded $7,500 and a business advisory package provided by MaRS Business Services, valued at $2,500.

Above: From left, Schulich Professor Amin Mawani, MBA students Aravind Petlu and Nilotpala Jena, and scientist Herman Lo

The second place award of $5,000 went to ViewsIQ Inc. for its real-time slide-scanning system for digital pathology. The product, named EyesIQ, is a diagnostic tool for scanning, storing and retracing pathologists' image data. The team included scientist Herman Lo and MBA students Aravind Petlu and Nilotpala Jena.

The team awarded third place and a cash prize of $2,500 was J. Strupat Technologies Ltd. for a portable pandemic ventilator life-critical system that provides mechanical assistance to individuals who are unable to breathe properly due to infection or physical damage. The team was comprised of scientist John Strupat and MBA students Darryl Baptiste and Akyljan Noupbaev.

Above: From left, Janet Lambert (contest judge), MBA students Akyljan Noupbaev and Darryl Baptiste, and scientist John Strupat

Fostering an entrepreneurial culture is integral to this competition, says Janet LeClair, chief administrative officer of , who organized the competition along with Schulich Professor Amin Mawani. “Such collaboration between scientific, business and academic communities is essential in connecting concept to commerce,” LeClair says. “The competition helps in identifying investment opportunities critical to move the economy forward.”

sanofi pasteur was the gold sponsor for the competition, MaRS and the Town of Markham were silver sponsors, while bronze sponsors were the Health Technology Exchange and 91��ɫ Region District School Board.

About YORKbiotech Inc.

YORKbiotech is a growing cluster of public- and private-sector members that promotes the convergence and commercialization of research and development in information & communications technologies and biomedical technologies.

Its members include biotechnology-related companies from Toronto through 91��ɫ Region to Simcoe County, along with service providers, industry associations, research and educational institutions, municipalities, hospitals and government.

It is one of 12 active clusters in , which supports partnerships among business, institutions and local governments to promote innovation. 91��ɫ is a founding member of YORKbiotech.

By Sana Mulji Dutt. Republished courtesy of YFile – 91��ɫ’s daily e-bulletin.

Thanks also to the .

The post YORKbiotech announces winners of Sanofi pasteur Healthcare and Biotechnology Venture Challenge appeared first on Research & Innovation.